CTI BioPharma (NASDAQ:CTIC) released its earnings results on Thursday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.19), Bloomberg Earnings reports. The company had revenue of $0.42 million for the quarter. CTI BioPharma had a negative net margin of 224.53% and a negative return on equity of 67.97%.
CTI BioPharma stock traded down $0.05 during mid-day trading on Friday, reaching $0.69. 364,463 shares of the company’s stock were exchanged, compared to its average volume of 146,326. CTI BioPharma has a twelve month low of $0.60 and a twelve month high of $2.34. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.18. The stock’s fifty day simple moving average is $0.83.
About CTI BioPharma
Read More: What is the NASDAQ?
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.